NOV 24, 2017 10:34 AM PST

Discovery of Compound Provides New Hope for Treating Autoimmune Disease

WRITTEN BY: Kara Marker

The majority of drugs available for people with autoimmune diseases are only designed to alleviate symptoms, as opposed to targeting the root cause of disease. Thanks to the discovery of a new “drug-like compound,” University of Colorado at Boulder scientists believe they can work toward the development of new drugs that target the cause instead of just the symptoms.

Toll-like receptor 2 (TLR2). Credit: European Bioinformatics Institute

The new discovery starts with a component of the innate, or non-specific, immune system called toll-like receptor 8 (TLR8). Upon sensation of a pathogen, TLR8 triggers a domino reaction that changes the receptor from a passive state to an active state. Activate TLR8 releases inflammatory signals that are good for fighting bacteria and viruses, but bad for healthy tissues if the response goes overboard.

Historically, TLR8 has been difficult to study and apply as a drug target because it is “hidden inside the endosome,” while most drug targets are on the cell’s surface. The new CU Boulder study, in an effort to find a molecule to bind TLR8, completed high-throughput screening of more than 14,000 small molecule compounds. Out of the thousands, researchers zeroed in on just four with the potential to have the proper chemical structure for the job.

Using these four small molecules as a model, researchers chemically synthesized their own compound to bind TLR8, preventing TLR8 activity instead of silencing an already-active TLR8. "Before, people were trying to close the open door to shut it down. We found the key to lock the door from the inside so it never opens," explained lead author Hang Hubert Yin.

Yin calls the new synthesized compound and the approach to blocking TLR8 activation “paradigm shifting.”

In the future, Yin and his team plan on continuing their studies of the new TLR8-binding compound and its potential to treat a variety of autoimmune diseases that cause pain, inflammation, and other chronic health issues. Existing drugs can be costly and cause side effects, so the new compound could be the answer for many scientists looking for alternatives.

Yin is planning animal studies and human clinical trials, to learn more about TLR8 and other toll-like receptors.

The present study was published in the journal Nature Chemical Biology.

Source: University of Colorado at Boulder

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
JUL 17, 2018
Videos
JUL 17, 2018
Encouraging Progress on HIV Vaccine
In the quest to find a vaccine against HIV which causes AIDS, most attempts have failed. The HIV epidemic began about 35 years ago and in that time only fi...
AUG 31, 2018
Immunology
AUG 31, 2018
B Cells Control Connective Tissue Disorder Scleroderma
Effector and Regulatory B cells play reciprocal role in pathogenesis of scleroderma....
OCT 03, 2018
Cell & Molecular Biology
OCT 03, 2018
Single Cell Modified in CAR T Therapy Causes Deadly Relapse
One cell meant a very different outcome for a patient that was the recipient of a cutting-edge cancer therapy....
OCT 16, 2018
Drug Discovery
OCT 16, 2018
Immunotherapeutic Targets A Blood-Clotting Protein
Fibrin is a blood protein that normally does not cross to the brain, however, several neurological disorders have a defect in the blood-brain barrier that ...
OCT 16, 2018
Drug Discovery
OCT 16, 2018
Potential Targeted Treatment for Crohn Disease
Emerging as a global disease with rates increasing the past 5 decades, Crohn’s disease (CD) is the chronic inflammation of the intestinal tract. Now,...
NOV 07, 2018
Immunology
NOV 07, 2018
Herd Protection Against Measles
A 26-year-old leukemia patient dies from exposure to measles. Herd immunity can offer a level of protection for those with impaired immune systems....
Loading Comments...